Tumor vascular disrupting agents

Recent Advances in Angiogenesis and Antiangiogenesis

Volumn , Issue , 2009, Pages 101-111

  Tozer, Gillan ^a   Kanthou, Chyso ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884445531     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/97816080500481090101101     Document Type: Chapter

References (94)

1. Neri D, Bicknell R. Tumor vascular targeting. Nat Rev Cancer 2005; 5(6): 436-46.
2. Schliemann C, Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 2007; 1776(2): 175-92.
3. Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003; 88(12): 1844-50.
4. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008; 99(12): 2006-12.
5. Baguley BC, Holdaway KM, Thomsen LL, et al. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27: 482-487.
6. Hill SA, Lonergan SJ, Denekamp J, et al. Vinca alkaloids: anti-vascular effects in a murine tumor . Eur J Cancer 1993; 9: 1320-1324.
7. Lin CM, Ho HH, Pettit GR, et al. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989; 28: 6984-6991.
8. Pettit GR, Cragg GM, Singh SB. Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod 1987; 50: 386-391.
9. Pettit GR, Temple C, Narayanan VL,et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 1995; 10: 299-309.
10. Chaplin DJ, Pettit GR, Parkins CS, et al. Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents. Br. J. Cancer 1996; 74 (Suppl. XXVII): S86-S88.
11. Dark GD, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997; 57: 1829-1834.
12. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999; 59: 1626-1634.
13. Nathan PD, Judson I, Padhani A, et al. A Phase I Study of the Safety, Tolerability and Antitumor Activity of Escalating Doses of Combretastatin A4 Phosphate (CA4P) Given in Combination with Bevacizumab to Subjects with Advanced Solid Tumors -Final results. J Clin Oncol 2008; 26(Suppl): 3550.
14. Pettit GR, Lippert III JW. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 2000; 15: 203-216.
15. Holwell SE, Bibby MC. Activity of combretastatin A1 phosphate in murine models of liver metastasis. Br J Cancer 2001; 85 Supp 1-34.
16. Hill SA, Tozer GM, Chaplin DJ. Preclinical evaluation of the antitumor activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 2002; 22: 1453-1458.
17. Holwell SE, Cooper PA, Grosios K, et al. Combretastatin A-1 phosphate a novel tubulinbinding agent with in vivo vascular effects in experimental tumor s. Anticancer Res 2002; 22: 707-711.
18. Hua J, Sheng Y, Pinney KG, et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 2003; 23(2B): 1433-1440.
19. Hori K, Saito S Nihei Y, et al. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 1999; 90: 1026-1038.
20. Nihei Y, Suga Y, Morinaga Y. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 1999; 90: 1016-1025.
21. Hori K, Saito S, Sato Y. Stoppage of blood flow in 3-methylcholanthrene-induced primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med Sci Monit 2001; 7: 26-33.
22. Hori K, Saito S, Kubota K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumor blood flow and inhibits growth of tumor s developing in various tissues and organs. Br J Cancer 2002; 86(10): 1604-1614.
23. Davis PD, Hill SA, Galbraith SM, et al. J. In ZD6126: a new agent causing selective damage of tumor vasculature, 91st Annual Meeting of the American Association for Cancer Research, San Francisco, 2000; p 329.
24. Corada M, Zanetta L, Orsenigo F, et al. A monoclonal antibody to vascular endothelialcadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 2002; 100(3): 905-911.
25. Blaschuk OW, Rowlands TM. Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metastasis Rev 2000; 19(1-2): 1-5.
26. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413-6422.
27. Chen G, Horsman MR, Pedersen M, et al. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumor s. Acta Oncol 2008; 47(6): 1071-1076.
28. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99: 2060-2069.
29. Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005; 115(11): 2992-3006.
30. Kanthou C, Tozer GM. Tumor targeting by microtubule-depolymerizing vascular disrupting agents. Exp Opin Ther Targets 2007; 11: 1443-1457. 31. Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels. Nat Rev Cancer 2005; 5(6): 423-35.
31. Ching LM, Goldsmith D, Joseph WR, et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 1999: 59 (14): 3304-7.
32. Zhao L, Ching LM, Kestell P, et al. The antitumor activity of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 2002; 87(4): 465-470.
33. Wang LC, Reddy CB, Baguley BC, et al. Induction of tumor necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem Pharmacol 2004; 67(5)937-945.
34. Kallinowski F, Schaefer C, Tyler G, et al. In vivo targets of recombinant human tumor necrosis factor-?: blood flow, oxygen consumption and growth of isotransplanted rat tumor s. Br. J. Cancer 1989; 60: 555-560.
35. Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol 2002; 39(4-5): 187-199.
36. Zhao L, Marshall ES, Kelland LR, et al. Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest New Drugs 2007; 25(3): 271-276.
37. Wallace A, LaRosa DF, Kapoor V, et al. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res 2007; 67(14): 7011-7019.
38. Roberts ZJ, Goutagny N, Perera PY, et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 2007; 204(7): 1559-1569.
39. Roberts ZJ, Ching LM, Vogel SN. IFN-betadependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). J Interferon Cytokine Res 2008; 28(3): 133-139.
40. Wang LC, Ching LM, Paxton J W, et al. Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. Invest New Drugs 2008.
41. Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumor angiogenesis. Nat Rev Cancer 2008; 8(8): 618-631.
42. Reyes-Aldasoro CC, Wilson I, Prise VE, et al. Estimation of Apparent Tumor Vascular Permeability from Multiphoton Fluorescence Microscopic Images of P22 Rat Sarcomas In Vivo. Microcirculation 2008; 15: 65-79.
43. Chung F, Liu J, Ching LM, et al. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. Cancer Chemother Pharmacol 2008; 61(3): 497-502.
44. Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumor blood flow stasis. Br J Cancer 2003; 89(7): 1334-1344.
45. Skliarenko JV, Lunt SJ, Gordon ML, et al. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res 2006; 66(4): 2074-2080.
46. Ley CD, Horsman MR, Kristjansen PE. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia 2007; 9(2): 108-112.
47. Prise VE, Honess DJ, Stratford MRL, et al. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 2002; 21: 717-726.
48. Nihei Y, Suzuki M, Okano A, et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999; 90: 1387-1396.
49. Baguley BC, Zhuang L, Kestell, P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 1997; 9(2): 55-60.
50. Alexander JS, Hechtman HB, Shepro, D. Serotonin induced actin polymerization and association with cytoskeletal elements in cultured bovine aortic endothelium. Biochem Biophys Res Commun 1987; 143(1): 152-158.
51. Lash CJ, Li AE, Rutland M, et al. Enhancement of the anti-tumor effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998; 78(4): 439-445.
52. Parkins CS, Holder AJ, Hill SA, et al. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 2000; 83: 811-816.
53. Badn W, Kalliomaki S, Widegren B, et al. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma. Clin Cancer Res 2006; 12(15): 4714-4719.
54. Yeung SC, She M, Yang H, et al. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 2007; 92(8): 2902-2909.
55. Kanthou C, Greco O, Stratford A, et al. The tubulinbinding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol 2004; 165(4): 1401-1411.
56. Ching LM, Cao Z, Kieda C, et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 2002; 86(12)1937-1942.
57. Sheng Y, Hua J, Pinney KG, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 2004; 111(4): 604-610.
58. Folkes LK, Christlieb M, Madej E, et al. Oxidative Metabolism of Combretastatin A-1 Produces Quinone Intermediates with the Potential To Bind to Nucleophiles and To Enhance Oxidative Stress via Free Radicals. Chem Res Toxicol 2007; 20: 1885-1894.
59. Kirwan IG, Loadman PM, Swaine DJ, et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 2004; 10(4): 1446-1453.
60. Horsman M, Ehrnrooth E, Ladekarl M, et al. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int. J. Radiat. Oncol. Biol. Phys. 1998; 42: 895-898.
61. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19: 189-196.
62. Grosios K, Holwell SE, McGown AT, et al. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 1999; 81: 1318-1327.
63. Pedley RB, Hill SA, Boxer GM, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-Ophosphate. Cancer Res 2001; 61(12)4716-4722.
64. Beauregard DA, Hill SA, Chaplin DJ, et al. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001; 61(18): 6811-6815.
65. Tozer GM, Akerman S, Cross NA, et al. Blood vessel maturation and response to vasculardisrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res 2008; 68(7); 2301-2311.
66. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21(15)2831-2842.
67. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990; 50: 4478-4484.
68. Murata R, Siemann DW, Overgaard J, et al. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001; 60(2): 155-161.
69. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 53(1); 164-171.
70. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66(24): 11520-11539.
71. Hori K, Furumoto S, Kubota K. Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth. Cancer Sci 2008; 99(7): 1485-1491.
72. Martinelli M, Bonezzi K, Riccardi E, et al. Sequence dependent antitumor efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007; 97(7): 888-894.
73. Grosios K, Loadman PM, Swaine DJ, et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Research 2000; 20: 229-234.
74. Li L, Rojiani A, Siemann D. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998; 42: 899-903.
75. Ng QS, Goh V, Carnell D, et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2007; 67(5): 1375-1380.
76. Pedley RB, Boden JA, Boden R, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flowmodifying agents. Cancer Res 1996; 56(14): 3293-3300.
77. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Nature 2005; 436(7050)568-572.
78. Fens MH, Hill KJ, Issa J,et al. Liposomal encapsulation enhances the antitumor efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. Br J Cancer 2008; 99(8); 1256-1264.
79. Pattillo CB, Sari-Sarraf F, Nallamothu R, et al. Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res 2005; 22(7)1117-1120.
80. El-Emir E, Boxer GM, Petrie IA, et al. Tumor parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 2005; 41(5): 799-806.
81. Boehle AS, Sipos B, Kliche U, et al. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 2001; 71: 1657-1665.
82. Dachs GU, Steele AJ, Coralli C, et al. Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 2006; 6: 280-291.
83. Shaked Y, Ciarrocchi A, Franco M, et al. Therapyinduced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313(5794): 1785-1787.
84. Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 2004; 60(4): 1233-1240.
85. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008; 28(4B): 2027-2031.
86. Tozer GM, Kanthou C, Lewis G, et al. Tumor vascular disrupting agents: combating treatment resistance. Br J Radiol 2008; 81(Spec No): S12-20.
87. Dong D, Ko B, Baumeister P, et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res 2005; 65(13): 5785-5791.
88. Galbraith SM, Rustin GJ, Lodge M A, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002; 20(18): 3826-3840.
89. Rustin GJ, Bradley C, Galbraith S, et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003; 88(8)1160-1167.
90. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62(12): 3408-3416.
91. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21(15)2815-2822.
92. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004; 10(1 Pt 1): 96-100.
93. Honess DJ, Hylands F, Chaplin DJ, et al. In Combretastatin-A-4-P induced hypertension can be controlled with conventional antihypertensive therapy in a rat model without compromising the reduction in tumor blood flow, AACR 96th Annual Meeting 2005, Anaheim, Orange County, CA, U.S.A., 2005: p 704.
94. Gould S, Westwood FR, Curwen JO, et al. Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Inst 2007; 99(22): 1724-1728.